Trial Profile
Randomized phase II study with S-1 (4week treatment and 2week rest) or S-1 (Alternate day administration) adjuvant chemotherapy for patients with pancreatic cancer
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 19 Jun 2019
Price :
$35
*
At a glance
- Drugs Gimeracil/oteracil/tegafur (Primary)
- Indications Ductal carcinoma; Pancreatic cancer
- Focus Therapeutic Use
- 25 Jun 2013 New trial record